Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men
Diabetes, Obesity and Metabolism · 2026-10-14
DOI: 10.1111/dom.71433 ↗At a glance
Journal article in Diabetes, Obesity and Metabolism, published online on 2026-10-14. Written by Thomas Brevig and 10 co-authors. Institution: Global Medical Division, Gedeon Richter Plc., Budapest, Hungary. 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Gedeon Richter Plc.
Abstract (original language)
Aim
This Phase 1 program evaluated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of the novel melanin‐concentrating hormone receptor‐1 antagonist RGH‐706.
Methods
Study A was a first‐in‐man, randomized trial comprising a double‐blind, placebo‐controlled single‐ascending‐dose part (0.1–162.5 mg) and a two‐way crossover food‐effect assessment at 62.5 mg in healthy men. Study B was a double‐blind, placebo‐controlled, single‐ and multiple‐ascending‐dose study in overweight or obese (otherwise healthy) men receiving a single dose followed by 14 days of once‐daily dosing (2.5–22.5 mg/day). Safety assessments included clinical evaluations, ECGs and mood and sleep scales. RGH‐706 concentrations in plasma and urine samples were measured by validated methods. Pharmacokinetics was characterized using non‐compartmental analysis. Study B evaluated exploratory pharmacodynamic measures including appetite‐related outcomes, food preference, test‐meal food and macronutrient intake, body composition and metabolic biomarkers.
Results
In Study A ( n = 68), systemic exposure increased approximately dose proportionally up to 62.5 mg and more than proportionally above, with t max between 2.5 and 3.5 h and a bi‐exponential disposition with a 29–35 h terminal half‐life. Food ingestion had a negligible effect on exposure and renal clearance was also negligible. In Study B ( n = 36), RGH‐706 showed moderate accumulation with steady state reached within 8 days. Exploratory pharmacodynamic measures showed a trend towards lower total energy intake, preference for fatty foods and weight gain, primarily with the lower doses of 2.5 and 7.5 mg/day. RGH‐706 was well tolerated across all doses and conditions in both studies.
Conclusions
RGH‐706 was safe, well tolerated and exhibited well‐characterized pharmacokinetics. The pharmacodynamic data support further exploration of RGH‐706 in weight management.
Subjects
Author keywords
Authors and institutions
- Global Medical Division, Gedeon Richter Plc., Budapest, Hungary.
- Developmental Drug Metabolism & Pharmacokinetics, Gedeon Richter Plc., Budapest, Hungary.
ORCID profiles: Zsófia Borbála Dombi, Gabriella Magyar
Funding
- Gedeon Richter Plc
Cite
APA
Brevig, T., Szepes, B., Dombi, Z. B., Magyar, G., Juhász, Z., Kapás, M., Cseh, É., Hegedűs, Z., Farkas, T., Kiss, Z., & Szatmári, B. (2026). Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71433
Vancouver
Brevig T, Szepes B, Dombi ZB, Magyar G, Juhász Z, Kapás M, et al. Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71433
BibTeX
@article{Brevig2026,
author = {Brevig, Thomas and Szepes, Borbála and Dombi, Zsófia Borbála and Magyar, Gabriella and Juhász, Zoltán and Kapás, Margit and Cseh, Éva and Hegedűs, Zsuzsa and Farkas, Tibor and Kiss, Zsuzsanna and Szatmári, Balázs},
title = {Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71433}
}
EUVIMED